Introduction {#s1}
============

Enterococci, particularly *Enterococcus faecalis* and *Enterococcus faecium*, are among the leading pathogens isolated from nosocomial infections.^[@DKQ087C1],[@DKQ087C2]^ Despite the availability of a number of antimicrobial agents to treat enterococcal infections, a substantial proportion of patients do not achieve adequate outcomes,^[@DKQ087C1],[@DKQ087C3]--[@DKQ087C5]^ due in part to an increase in the proportion of enterococcal strains that are resistant to one or more of these agents.^[@DKQ087C6]--[@DKQ087C10]^ Additional therapeutic options are, therefore, required for effective management of such patients.

Daptomycin is a cyclic lipopeptide that has rapid bactericidal activity against a broad spectrum of Gram-positive bacteria.^[@DKQ087C11],[@DKQ087C12]^ It is indicated for the treatment of complicated skin and soft tissue infections (cSSTIs) caused by susceptible Gram-positive bacteria, right-sided infective endocarditis (RIE) due to *Staphylococcus aureus*, and *S. aureus* bacteraemia (SAB) when associated with RIE or cSSTI.^[@DKQ087C12]^ In clinical practice, daptomycin is commonly used to treat enterococcal infections (often in patients with multiple co-morbidities), occasionally at doses higher than 6 mg/kg, the approved dosage to treat SAB.^[@DKQ087C12]^

There is a growing body of *in vitro* and clinical evidence suggesting that daptomycin has good activity against enterococci. This article evaluates the evidence for the role of daptomycin in this clinical setting.

*In vitro* activity of daptomycin against enterococci {#s2}
=====================================================

Several studies have compared the activity of daptomycin against clinical isolates of enterococci with those of currently licensed agents (Table [1](#DKQ087TB1){ref-type="table"}).^[@DKQ087C8],[@DKQ087C9],[@DKQ087C13]--[@DKQ087C18]^ In a surveillance study of clinical isolates recovered during 2002--08 in the USA, \>99.9% of 4496 *E. faecalis* and \>99.5% of 2875 *E. faecium* isolates were susceptible to daptomycin, with MIC~90~s of 1 and 4 mg/L, respectively.^[@DKQ087C18]^ These results were confirmed by European surveillance carried out between 2005 and 2007 that included 3385 strains of enterococci, which showed a daptomycin susceptibility rate of 100%, with the MIC~90~s of daptomycin for *E. faecalis* and *E. faecium* being 1 and 2 mg/L, respectively.^[@DKQ087C15]^ In both studies, the MIC~90~ of daptomycin was at or below the CLSI daptomycin susceptibility breakpoint for enterococci of ≤4 mg/L, which also corresponds to the epidemiological cut-off values for *E. faecalis* and *E. faecium* established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST).^[@DKQ087C19],[@DKQ087C20]^ Daptomycin demonstrated excellent *in vitro* activity against enterococcal isolates recovered from patients at high risk of developing infections due to antibiotic-resistant bacteria, such as patients with cancer or in intensive care units.^[@DKQ087C17],[@DKQ087C21]^ Studies have also shown that other enterococcal species, including *Enterococcus durans, Enterococcus avium, Enterococcus casseliflavus, Enterococcus gallinarum* and *Enterococcus raffinosus*, are susceptible to daptomycin.^[@DKQ087C22]--[@DKQ087C24]^

###### 

Susceptibility of enterococci to antibiotic agents in multicentre, comparative studies worldwide

                                                                                                                           Daptomycin   Linezolid   Vancomycin   Quinupristin/dalfopristin                              
  ---------------------- ------------ ----------------------------------------- ----------------------------------- ------ ------------ ----------- ------------ --------------------------- ------ ------ ----- ------ --------------
  2006                   USA          bacteraemia, wound or other infections    enterococci                         547    2            99.8        2            97.4                        \>16   71.7   \>2   31.1   [@DKQ087C8]
  2004--05               Europe       various infection types                   VSE                                 484    4            100         2            99.8                        0.5    99.8   ND    ND     [@DKQ087C9]
  VRE                    195          4                                         100                                 2      100          ≥64         21.7         ND                          ND                         
  2007                   Europe       various infection types                   VSE                                 542    4            100         2            95.4                        0.5    100    ND    ND     [@DKQ087C9]
  VRE                    187          4                                         100                                 2      95.7         ≥64         21.4         ND                          ND                         
  2005--07               Europe       bloodstream, skin or other infections     VSE                                                                                                                                     [@DKQ087C15]
   *E. faecium*          853          2                                         100                                 2      99.8         1           100          \>2                         70.6                       
   *E. faecalis*         2133         1                                         100                                 2      100          2           100          \>2                         0.9                        
  VRE                                                                                                                                                                                                                   
   *E. faecium*          267          2                                         100                                 2      99.3         \>16        0            \>2                         78.3                       
   *E. faecalis*         18           1                                         100                                 2      100          \>16        0            \>2                         0                          
  2002--05               USA/Canada   various infection types                   VSE                                 3336   2            99.9        2            99.8                        ND     ND     \>2   11.2   [@DKQ087C14]
  VRE                    1560         4                                         99.4                                2      98.5         ND          ND           2                           86.9                       
  2005--08               Europe       bloodstream infections                    vancomycin-resistant *E. faecium*   134    2            99.3        2            98.5                        ND     ND     \>2   73.1   [@DKQ087C16]
  2005--06               Canada       various infection types in ICU patients   *E. faecalis*                       91     1            100         2            92.3                        2      97.8   ND    ND     [@DKQ087C17]
  *E. faecium*           29           2                                         100                                 8      34.5         \>64        72.4         ND                          ND                         
  VRE                    17           1                                         100                                 4      64.7         \>64        0            ND                          ND                         
  other enterococci      135          1                                         100                                 2      97.2         2           94.7         ND                          ND                         
  2007--08               USA/Korea    blood or skin infections                  *E. faecalis* (USA/Korea)           455    2            100         2            96.9                        4      96.0   32    0.9    [@DKQ087C13]
  *E. faecium* (Korea)   184          4                                         100                                 2      95.7         \>128       73.4         4                           78.8                       
  *E. faecium* (USA)     205          4                                         98.5                                4      85.9         \>128       20.0         2                           71.7                       

ICU, intensive care unit; ND, not determined; VRE, vancomycin-resistant enterococci; VSE, vancomycin-susceptible enterococci.

All MIC data were measured using broth microdilution.

Activity of daptomycin against enterococci growing as biofilms {#s2a}
--------------------------------------------------------------

Biofilms are populations of bacterial cells attached irreversibly on various human and artificial surfaces and encased in a hydrated matrix mainly composed of exopolymeric substances and polysaccharides. According to the NIH in the USA, biofilms account for \>80% of microbial infections in the body.^[@DKQ087C25]^ It has been suggested that the ability of enterococci to form biofilms may be facilitated by the production of enterococcal surface protein.^[@DKQ087C26]--[@DKQ087C28]^ Enterococci develop persistent biofilms on a wide variety of medical devices that are commonly used in hospitalized patients, and this may partially explain why they are one of the leading causes of nosocomial infections.

Biofilms are difficult to eradicate because they restrict the diffusion and target accessibility of antimicrobial agents. Moreover, bacterial cells in biofilms (sessile bacteria) have slower growth rates and can tolerate 10- to 1000-fold higher concentrations of antibiotics than planktonic bacteria.^[@DKQ087C27]^ Therefore, the biofilm matrix is generally considered as a platform for the development of drug-resistant bacteria. The persistence of biofilms on medical devices may contribute to prolonged infection, thereby increasing the opportunity for patient-to-patient transmission.

The eradication of biofilms requires an antibiotic that can effectively penetrate the biofilm matrix and is active against slow-growing bacteria. Daptomycin is bactericidal against stationary-phase bacteria and has good penetration into the biofilm matrix to effectively reduce bacterial growth.^[@DKQ087C29],[@DKQ087C30]^ In contrast, some reports have shown ineffective killing of *E. faecalis* growing in biofilms using vancomycin.^[@DKQ087C31],[@DKQ087C32]^ In an *in vitro* biofilm model (using silicone discs), daptomycin was significantly superior to quinupristin/dalfopristin and linezolid in reducing the growth of vancomycin-resistant *E. faecalis* isolated from patients with catheter-related bacteraemia (*P* \< 0.01; Table [2](#DKQ087TB2){ref-type="table"}).^[@DKQ087C33]^

###### 

Daptomycin demonstrated superior activity over comparator antibiotics in reducing the growth of 22 vancomycin-resistant *E. faecalis* isolates from catheter-related bacteraemia patients in biofilms (extracted from the study by Raad *et al.*^[@DKQ087C33]^)

  Antibiotic or control       MIC range (mg/L)   Biofilm (mean cfu per disc ± SEM)^a^
  --------------------------- ------------------ --------------------------------------
  Daptomycin                  2.0--8.0           1.3 × 10^2^ ± 2.7 × 10^1^
  Minocycline                 ≥0.06--8.0         5.6 × 10^2^ ± 1.2 × 10^2^
  Quinupristin/dalfopristin   ≥0.06--2.0         3.0 × 10^3^ ± 1.8 × 10^2^
  Linezolid                   0.5--2.0           4.3 × 10^3^ ± 1.4 × 10^2^
  Control (water)             NA                 5.0 × 10^3^ ± 0

NA, not applicable; SEM, standard error of the mean.

^a^Colonization data are after 24 h of exposure to 2000 mg/L antibiotic.

All antibiotics significantly reduced biofilm colonization compared with the control (*P* ≤ 0.01). Daptomycin was more effective than minocycline (*P* \< 0.001). Minocycline was significantly more effective than quinupristin/dalfopristin (*P* \< 0.01) and quinupristin/dalfopristin was significantly more effective than linezolid (*P* \< 0.01). A total of 660 discs were tested using six discs per isolate plus a particular antibiotic or water.

Activity of daptomycin against antibiotic-resistant enterococci {#s2b}
---------------------------------------------------------------

The increasing prevalence of infections caused by vancomycin-resistant enterococci (VRE) has been documented globally.^[@DKQ087C10],[@DKQ087C34]^ Enterococcal strains resistant to several non-glycopeptide antibiotic agents, including ampicillin, quinupristin/dalfopristin and/or linezolid, have also been reported.^[@DKQ087C7]--[@DKQ087C9]^

In a recent surveillance study performed across 50 medical centres in the USA, 28% of enterococci isolates were resistant to vancomycin.^[@DKQ087C8]^ Moreover, surveillance of enterococcal infections in the USA showed that between 2002 and 2008, only 20.2% of *E. faecium* isolates (*n* = 2875) were susceptible to vancomycin.^[@DKQ087C18]^ In Europe, the VRE rate increased from 4.5% in 2006 to 10.2% in 2007, although the prevalence varied significantly from country to country. For example, in 2007 there were no reports of VRE in either Switzerland or Spain, but the prevalence of VRE was 25.8% and 23.8% in Ireland and Poland, respectively. Among *E. faecium* strains, the vancomycin resistance rate in Europe increased from 17.9% in 2005 to 26.3% in 2007.^[@DKQ087C15]^ Similar trends were seen in the European Antimicrobial Resistance Surveillance System (EARSS).^[@DKQ087C10],[@DKQ087C35]^

Resistance to vancomycin is conferred by a number of *van* genes, of which *vanA* and *vanB* are the most prevalent.^[@DKQ087C7],[@DKQ087C10]^ In 2007, 76% of VRE isolates in North America and 40% of isolates in Europe exhibited the VanA phenotype.^[@DKQ087C7]^ Although the majority of clinical enterococcal isolates are *E. faecalis*, *E. faecium* is the more prevalent species among VRE.^[@DKQ087C7],[@DKQ087C28]^ The increase in the incidence of VRE in the hospital setting is mainly due to the emergence of vancomycin resistance among a subpopulation of *E. faecium* known as clonal complex 17 (CC17).^[@DKQ087C7],[@DKQ087C28]^ Nearly all *E. faecium* isolates belonging to CC17 are resistant to ampicillin and partially resistant to quinolones. CC17 *E. faecium* isolates also possess additional genetic determinants, including putative virulence genes, such as those encoding different cell wall-anchored surface proteins.^[@DKQ087C28]^ It appears that a large number of genes acquired by CC17 *E. faecium* contribute to its selective advantage; this, together with its inherent antibiotic resistance, facilitates the further dissemination of VRE in the hospital environment.^[@DKQ087C28],[@DKQ087C36]^ Daptomycin has effective *in vitro* activity against *E. faecium* isolates belonging to CC17 (P. Ruiz-Garbajosa, T. M. Coque, F. Baquero and R. Cantón, unpublished data).

As the mode of action of daptomycin is distinct from that of glycopeptides, its activity against enterococci is unaffected by the presence of the *van* genes. Studies have shown that most enterococci are susceptible to daptomycin, irrespective of their resistance towards vancomycin.^[@DKQ087C8],[@DKQ087C14]--[@DKQ087C16],[@DKQ087C22],[@DKQ087C37]^ Among VRE, daptomycin MICs ranged from 1 to 4 mg/L for isolates with the VanA phenotype,^[@DKQ087C38]^ and daptomycin was also active against those with VanB or VanC phenotypes.^[@DKQ087C22]^ In an analysis of the antimicrobial susceptibility of Gram-positive bacteria collected in European and Israeli medical centres from 2005 to 2007, all 285 VRE isolates were susceptible to daptomycin. The MIC~90~s of daptomycin for vancomycin-non-susceptible *E. faecalis* and *E. faecium* were 1 and 2 mg/L, respectively.^[@DKQ087C15]^ When tested against bloodstream isolates, 99.3% of vancomycin-resistant *E. faecium* isolates were susceptible to daptomycin, 98.5% to linezolid and 73.1% to quinupristin/dalfopristin.^[@DKQ087C16]^ Daptomycin showed greater inhibitory activity against glycopeptide-resistant enterococci (GRE) than linezolid (MIC~90~ 1.5 mg/L versus 4.0 mg/L),^[@DKQ087C37]^ and was also more active against VRE than linezolid or quinupristin/dalfopristin in time--kill studies.^[@DKQ087C11]^

Furthermore, *in vitro* time--kill, agar diffusion and chequerboard studies demonstrated synergistic effects of daptomycin with rifampicin or ampicillin against VRE, including linezolid-resistant strains. No antagonism of daptomycin with these agents was seen.^[@DKQ087C39]--[@DKQ087C41]^ Other *in vitro* data also showed that daptomycin has non-antagonistic effects with gentamicin and β-lactams against vancomycin-susceptible enterococci and VRE,^[@DKQ087C42]^ suggesting that combination therapy may be beneficial in certain clinical situations, such as in neutropenic patients.^[@DKQ087C43]^ Nevertheless, clinical data for this beneficial effect are still scarce.

Additional reports have documented that enterococci are frequently also resistant to antibiotics other than vancomycin. In the 2005 SENTRY antimicrobial surveillance programme, which evaluated 953 enterococci isolates from medical centres in 10 European countries, Turkey and Israel, 49.5% and 29.2% of the isolates were resistant to ciprofloxacin and ampicillin, respectively.^[@DKQ087C44]^ This could possibly be a consequence of CC17 *E. faecium* expansion.^[@DKQ087C28]^ The programme also found quinupristin/dalfopristin to be inactive against 10% of *E. faecium* isolates.^[@DKQ087C7]^ As expected, daptomycin activity against enterococci was not influenced by their susceptibility to ampicillin or quinupristin/dalfopristin.^[@DKQ087C22],[@DKQ087C45]^ Furthermore, of 1000 *E. faecium* clinical isolates tested in Greece, 2.5% were resistant to linezolid and 15% were resistant to quinupristin/dalfopristin, but none was resistant to daptomycin. As in previous studies, there were no differences in daptomycin MICs for isolates that were resistant or susceptible to other antibiotics. In particular, the activity of daptomycin was not reduced against enterococci resistant to vancomycin or linezolid.^[@DKQ087C45]^ Daptomycin also demonstrated rapid bactericidal activity against ampicillin-resistant enterococci, and its activity was not compromised when tested simultaneously with aminoglycosides.^[@DKQ087C46]^ Other *in vitro* studies also showed daptomycin to be bactericidal against aminoglycoside-resistant or penicillinase-producing enterococci.^[@DKQ087C47]^

Linezolid-resistant enterococci have been isolated from clinical *s*pecimens.^[@DKQ087C8],[@DKQ087C9],[@DKQ087C48]^ Surveillance in the USA during 2006 showed that nearly 2% of enterococci tested were resistant to linezolid,^[@DKQ087C8]^ while in Europe the frequency of enterococci non-susceptible to linezolid increased from 0.1% in 2004/2005 to 4.7% in 2007.^[@DKQ087C9]^ A German study of 60 clinical isolates reported that a high proportion of glycopeptide-resistant *E. faecium* (82%) exhibited intermediate susceptibility to linezolid,^[@DKQ087C37]^ which could be due to over-representation of specific GRE strains due to clonal spread.^[@DKQ087C49],[@DKQ087C50]^ In all these studies, daptomycin remained active against enterococci regardless of the susceptibility to linezolid, with MICs ranging from 0.06 to 4 mg/L.^[@DKQ087C9]^ In a separate *in vitro* study of linezolid-resistant clinical isolates, daptomycin inhibited all enterococcal isolates (*n* = 68) at ≤4 mg/L, and the majority of *E. faecalis* (93.3%) and *E. faecium* (94.3%) strains had daptomycin MICs of ≤1 and ≤2 mg/L, respectively.^[@DKQ087C51]^

Evidence from animal models {#s3}
===========================

*In vivo* evidence further suggests the efficacy of daptomycin in enterococcal infections, including those involving GRE. In a rat model of endocarditis, daptomycin at standard recommended human doses (6 mg/kg every 24 h) showed similar efficacy to amoxicillin and vancomycin, and was significantly (*P* \< 0.05) more effective than teicoplanin against glycopeptide-susceptible *E. faecalis* isolates. Moreover, daptomycin was also superior to teicoplanin in the treatment of endocarditis due to VanB vancomycin-resistant *E. faecium*.^[@DKQ087C52]^ These results are consistent with the findings of an *in vitro* model of simulated endocardial vegetations. In this model, a simulated regimen of daptomycin at 6 mg/kg every 24 h demonstrated significant bactericidal activity against a strain of vancomycin-resistant *E. faecium*.^[@DKQ087C53]^ Another study showed that high-dose daptomycin (12 mg/kg), alone or in combination with gentamicin, was effective in a rabbit model of endocarditis caused by *E. faecium*.^[@DKQ087C54]^ Daptomycin also showed rapid bactericidal activity against vancomycin-resistant *E. faecium* in a pharmacodynamic model, with no development of resistance despite subinhibitory antimicrobial activity.^[@DKQ087C55]^ In addition, studies with murine renal and thigh infection models showed that clinically relevant exposure to daptomycin was effective against enterococci.^[@DKQ087C56],[@DKQ087C57]^

Complementing data from *in vitro* time--kill studies, daptomycin demonstrated excellent bactericidal activity and dose-dependent reductions in bacterial counts in these animal models, supporting the potential benefits for the treatment of enterococcal infections in humans.

Clinical experience with daptomycin in enterococcal infections {#s4}
==============================================================

Considerable clinical experience with daptomycin in enterococcal infections is available in the form of published case reports, case series and the Cubicin Outcomes Registry and Experience (CORE^®^) database. CORE is a retrospective, post-marketing database that includes information on prescribing patterns and outcomes with daptomycin therapy in the USA.^[@DKQ087C58]^

Bacteraemia {#s4a}
-----------

Using the CORE database, Mohr *et al.*^[@DKQ087C59]^ analysed clinical outcomes of patients with enterococcal bacteraemia who were treated with daptomycin. A total of 159 patients with enterococcal bacteraemia, comprising 120 patients with *E. faecium* (91% vancomycin resistant) and 39 with *E. faecalis* (23% vancomycin resistant), were treated with daptomycin either as first-line therapy (17%) or after prior treatment with other antibiotic agents.^[@DKQ087C59]^ The overall clinical success rate was 87%, with similar rates between patients infected with *E. faecium* (87%) and those infected with *E. faecalis* (90%). Clinical outcomes were not influenced by the use of concomitant antibiotic therapy, and clinical success was reported in 87% of those patients who received prior vancomycin and 88% of patients who did not. The clinical outcome in relation to dosage schedule for daptomycin was not reported.^[@DKQ087C59]^

Vancomycin resistance is independently associated with increased mortality among patients with bacteraemia due to enterococci.^[@DKQ087C60],[@DKQ087C61]^ The fact that patients with bacteraemia due to VRE are also less likely to receive appropriate therapy than those with vancomycin-susceptible enterococcal bloodstream infections^[@DKQ087C62],[@DKQ087C63]^ highlights a lack of appropriate therapeutic options for these patients. The Infectious Diseases Society of America 2009 guidelines recommend the use of daptomycin for the treatment of catheter-related bacteraemia due to VRE or ampicillin-resistant enterococci in patients with or without dialysis.^[@DKQ087C64]^

A recent retrospective chart review included the medical records of 30 patients with bacteraemia due to VRE who received a median daptomycin dose of 6 mg/kg (range, 3.7--8 mg/kg). All isolates were susceptible to daptomycin, with MICs ranging from \<1 to 4 mg/L, and this is reflected in the microbiological cure rate of 80%, while clinical success was observed in 17 patients (59%). The authors suggested that the efficacy rate of daptomycin would have been higher if all patients received a 6 mg/kg/dose.^[@DKQ087C65]^ Segreti *et al.*^[@DKQ087C66]^ also reported a retrospective series of patients with bacteraemia due to Gram-positive bacteria who were treated with daptomycin. Among nine patients with bacteraemia without endocarditis due to VRE (most of whom had received previous therapy with vancomycin or linezolid), five achieved successful resolution of infection after treatment with daptomycin at 4--6 mg/kg (four received monotherapy and one received daptomycin in combination with tobramycin). Treatment was not successful in the remaining four patients who received 6 mg/kg daptomycin (three received concomitant aminoglycosides). All four of these patients died, but they all had other serious co-morbidities.^[@DKQ087C66]^ Two cases of bacteraemia due to VRE successfully treated with daptomycin at a dosage of 4 mg/kg were reported by Kvirikadze *et al.*;^[@DKQ087C67]^ a further case reported a patient with bacteraemia caused by a vancomycin-susceptible strain of *E. faecalis* unresponsive to vancomycin therapy who was also treated successfully with 12 mg/kg daptomycin.^[@DKQ087C68]^ Although daptomycin is not approved for the treatment of enterococcal bacteraemia, there is growing evidence from clinical practice that doses higher than the currently approved dose (e.g. 8--12 mg/kg once a day) may be required for optimal treatment of complicated enterococcal infections.^[@DKQ087C69]--[@DKQ087C71]^

Several reports have focused on the use of daptomycin for the treatment of enterococcal bacteraemia in neutropenic patients. In a study of 92 allogeneic haematopoietic stem cell recipients, 34 patients developed bloodstream infections, of which 14 (41%) were due to VRE (13 *E. faecium* and 1 *E. avium*). Ten of these patients received daptomycin, three of whom were reported as microbiological failures; however, the infecting strains remained susceptible to daptomycin *in vitro* in all three cases. This observation, coupled with the fact that all 10 patients treated with daptomycin had also received linezolid or other antibiotics, highlights the inherent difficulty in interpreting microbiological outcomes. In addition, the clinical picture was complicated by the presence of underlying conditions in these patients and the absence of a comparator group.^[@DKQ087C72]^ Nine febrile neutropenic patients with bacteraemia due to VRE (eight *E. faecium* and one *E. faecalis*) were treated with daptomycin in an open-label emergency-use trial. Four patients (44%) achieved clinical and/or microbiological cure; two patients died within 3 days of commencement of treatment, indicating the severity of their illnesses. No correlation between clinical or microbiological outcome and daptomycin dose (4 or 6 mg/kg) was apparent; in fact, the small number of patients makes it difficult to draw meaningful conclusions from this study.^[@DKQ087C69]^ More recently, treatment failure was observed in 13 of 31 bacteraemic patients treated with daptomycin, 6 of which were due to relapses within 1 month of initiation of initial infection.^[@DKQ087C73]^

Successful treatment with daptomycin combination therapy in patients with bacteraemia has also been reported.^[@DKQ087C43],[@DKQ087C74]^ In one case, a 21-day-old full-term infant developed bacteraemia due to vancomycin-resistant *E. faecium* 10 days after heart surgery (endocarditis was suspected but not confirmed). Bacteraemia persisted despite the removal of vascular catheters and treatment with antibiotics (including linezolid, quinupristin/dalfopristin, ampicillin/sulbactam and rifampicin). Microbiological cure was achieved with a combination regimen that initially included daptomycin (4 mg/kg every 48 h) in combination with gentamicin, but with the dose of daptomycin subsequently increased to 6 mg/kg every 24 h in combination with gentamicin and doxycycline.^[@DKQ087C74]^

Two retrospective studies have attempted to compare daptomycin with linezolid for the treatment of bacteraemia due to VRE. In a study by Mave *et al.*^[@DKQ087C75]^ in 98 adult patients, 68 of whom received linezolid and 30 of whom received daptomycin, the microbiological cure rates were 88.2% and 90%, respectively. No statistically significant differences in clinical outcomes were observed. Differences in the baseline characteristics of the treatment groups (significantly higher proportions of patients in intensive care units and patients with concomitant SAB in the daptomycin group) precluded any conclusive statements about the comparative performance of the two compounds. Similar results were described for daptomycin and linezolid in a study of neutropenic cancer patients by Marion *et al.*^[@DKQ087C76]^ Clearance of blood cultures was seen in 17 (81%) of 21 patients who received daptomycin, and 8 (80%) of 10 patients who were treated with linezolid. Relapse of infection was seen in 19.1% and 20% of the patient treatment groups, respectively. Overall mortality in the two patient cohorts was 52.3% and 60%, respectively.^[@DKQ087C76]^

Infective endocarditis (IE) {#s4b}
---------------------------

In an analysis of the CORE database, *Enterococcus* was identified as the primary pathogen in 14 of 49 patients with IE. Clinical success was reported in 10 of 14 patients \[9 with left-sided IE (LIE) and 1 with RIE\], and 2 patients failed daptomycin therapy (1 with LIE and 1 with RIE). Outcomes were not evaluable for the remaining two patients.^[@DKQ087C77]^ Case reports of daptomycin for IE caused by *Enterococcus* spp. have yielded various outcomes, including death in some cases (Table [3](#DKQ087TB3){ref-type="table"}). It should be noted, however, that all patients in these cases had significant underlying co-morbidities, with the majority failing prior antibiotic treatment. Daptomycin was usually given in combination with other antibiotics with no standardization as to concomitant treatment, and it was unclear whether cases of mortality were attributable to endocarditis or the underlying co-morbidity.

###### 

Case reports of endocarditis due to vancomycin-resistant enterococci treated with daptomycin

  Patient                                                                                                                                                
  --------- --- ---------------------------------------------------------- -------- ------------------------ ---------- -------------------- ----------- -----------------
  64        F   haemodialysis, prosthetic valve                            6        *Enterococcus* spp.^a^   TOB        none                 died        [@DKQ087C66]^b^
  51        M   not reported                                               6        *Enterococcus* spp.^a^   AMK        VAN                  died        [@DKQ087C66]^b^
  25        F   SLE, ESRD                                                  8        *E. faecium*             GEN, RIF   LZD                  died        [@DKQ087C103]
  62        M   diabetes, coronary and peripheral arterial disease, ESRD   6        *E. faecium*             TGC        VAN, LZD, MEM, FLC   recovered   [@DKQ087C104]
  60        M   diabetes                                                   6/8^c^   *E. faecium*             AMP, GEN   FEP, VAN             recovered   [@DKQ087C78]
  13        M   GVHD, pancreatitis                                         6/8^c^   *E. faecium*             NR         VAN, MEM, GEN        died        [@DKQ087C105]
  70        M   renal failure (receiving haemodialysis)                    6/8^c^   *E. faecium*             GEN, DOX   LZD                  failure     [@DKQ087C106]

AMK, amikacin; AMP, ampicillin; DOX, doxycycline; ESRD, end-stage renal disease; F, female; FEP, cefepime; FLC, fluconazole; GEN, gentamicin; GVHD, graft-versus-host disease; LZD, linezolid; M, male; MEM, meropenem; NR, not reported; RIF, rifampicin; SLE, systemic lupus erythematosus; TGC, tigecycline; TOB, tobramycin; VAN, vancomycin.

^a^Species not stated.

^b^Patients who were included in a CORE analysis.

^c^Initial dose of 6 mg/kg increased to 8 mg/kg.

One recent case report detailed successful combination treatment with high-dose daptomycin (8 mg/kg every 24 h), gentamicin (1 mg/kg every 12 h) and ampicillin (16 g every 24 h) in a patient with LIE caused by a strain of *E. faecium* 'heteroresistant' to vancomycin, but susceptible to daptomycin (MIC \< 4 mg/L). Previous treatment with daptomycin (6 mg/kg) monotherapy cleared blood cultures, but persistent vegetation was detected 5 weeks after the start of treatment and the patient refused valve replacement. Daptomycin monotherapy was halted and substituted by vancomycin plus gentamicin. These therapies were subsequently stopped after detection of VRE in blood cultures. Finally, the combination of high-dose daptomycin (8 mg/kg every 24 h), gentamicin and high-dose ampicillin (16 g every 24 h), given over 6 weeks, cured the infection.^[@DKQ087C78]^ In a separate case of endocarditis due to a strain of linezolid-resistant VRE (MICs: linezolid, 12 mg/L; and daptomycin, 3 mg/L), and the patient was successfully treated with high-dose daptomycin (started at 6 mg/kg every 24 h and subsequently increased to 8 mg/kg every 24 h) in combination with rifampicin, gentamicin and tigecycline.^[@DKQ087C79]^ Despite this evidence, more clinical data are needed to define the role of daptomycin (alone or in combination) therapy in enterococcal endocarditis.

Skin and soft tissue infections (including surgical site infections) {#s4c}
--------------------------------------------------------------------

In the pivotal studies, *E. faecalis* was the third most frequently treated pathogen (11.8%), and the clinical success rate among patients with cSSTI due to *E. faecalis* was 73.0% for daptomycin and 75.5% for the comparators (cloxacillin, flucloxacillin, nafcillin, oxacillin or vancomycin).^[@DKQ087C80]^ A report from the CORE database analysing patients with surgical site infections found that *Enterococcus* spp. were the second most common pathogen, being isolated from 23 (22%) of 104 evaluable patients. Eight of these 23 patients had VRE (7 *E. faecium*), of which 5 had organ/space infection. *Enterococcus* was considered to be the primary pathogen in 16 of these 23 patients, with clinical success reported for 14 (88%) patients. The success rate for patients with any VRE was 63% (five of eight patients). VRE was found to be an independent risk factor for treatment failure (odds ratio 14.2; 95% confidence interval 1.3--154).^[@DKQ087C81]^

In an analysis of 522 evaluable patients with skin and soft tissue infections registered in the CORE database in 2004, 337 patients (65%) yielded Gram-positive pathogens on culture, 63 (19%) of which were *Enterococcus* spp. that included 28 VRE cases. In 48 patients where an *Enterococcus* sp. was considered to be the primary pathogen, clinical success was noted in 44 patients (92%).^[@DKQ087C82]^

Bone and joint infections {#s4d}
-------------------------

The CORE database also collects data for patients receiving daptomycin for the treatment of osteomyelitis.^[@DKQ087C83]^ Clinical outcomes were evaluated at the end of therapy (EOT group) and for patients who had one or more follow-up post-treatment assessments 3--13 months after the end of therapy (PT group). Of 148 patients with osteomyelitis registered during 2004, 12 and 8 patients in the EOT and PT groups, respectively, had infections due to enterococci. Outcomes for patients in the EOT group with enterococcal infections were not reported, but six of the eight patients in the PT group where enterococci were considered to be the primary pathogen were reported as having successful clinical outcomes, while two patients failed therapy. This was similar to the overall clinical success rate of 82% (55 of 67 patients) in the PT group.

Other infections {#s4e}
----------------

A small number of publications documenting the use of daptomycin for the treatment of other enterococcal infections have appeared recently in the literature. Two reports concerned lower urinary tract infections (UTIs), which is a potential area of interest because ∼50% of the daptomycin dose is excreted as unchanged drug in urine over 24 h following intravenous administration.^[@DKQ087C84]^ One open-label, single-blinded study compared daptomycin and ciprofloxacin for the treatment of adults with complicated UTIs caused by Gram-positive pathogens.^[@DKQ087C85]^ A total of 68 patients were randomized to receive daptomycin (4 mg/kg every 24 h) or ciprofloxacin (400 mg every 12 h) for 5--14 days. Of 45 patients treated for enterococcal UTI, 22 patients with *E. faecalis* infections received daptomycin and 23 (21 with *E. faecalis* and 2 with *E. faecium* infections) received ciprofloxacin. The microbiological eradication rate was 81.8% (18 of 22 patients) for daptomycin and 78.3% (18 of 23 patients) for ciprofloxacin.^[@DKQ087C85]^ In a separate report, five hospitalized patients with UTIs due to multidrug-resistant VRE (species not indicated) were treated with 250 mg/day of daptomycin (equivalent to 1.4--3.7 mg/kg) for 5 days, because the authors speculated that urinary accumulation of daptomycin should allow for lower dosing. In all five patients, urine cultures 2 days after completion of therapy were negative, and follow-up 10--14 days after therapy revealed no recurrence of bacteriuria.^[@DKQ087C86]^ It should be noted that patients with enterococcal UTIs may be at risk of complications such as bacteraemia, and no strong rationale exists for the use of daptomycin doses lower than those doses shown to be safe in clinical studies,^[@DKQ087C80],[@DKQ087C87]^ and subsequently approved for cSSTI (4 mg/kg) and SAB with or without IE (6 mg/kg).^[@DKQ087C12]^

Daptomycin has also been used successfully in two patients receiving peritoneal dialysis for end-stage renal disease who developed peritonitis due to VRE.^[@DKQ087C88]^ Each patient was treated for 10 or 14 days with intraperitoneal daptomycin (20 mg/L), given every 4 h through peritoneal dialysate exchanges. The treatment was successful despite the known degradation of daptomycin in dextrose solution. A separate case report also showed that intraperitoneal daptomycin (15 mg/kg once weekly) was successful in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis due to vancomycin-resistant *E. faecium*.^[@DKQ087C89]^

Successful treatment of external ventricular drain-associated ventriculitis caused by *E. faecalis* with intraventricular daptomycin has also been reported.^[@DKQ087C90]^

Resistance of enterococci to daptomycin {#s5}
=======================================

Neither the CLSI nor the EUCAST committees have defined resistance breakpoints for enterococci to daptomycin. According to the CLSI, enterococci isolates with daptomycin MICs ≤4 mg/L are considered susceptible to the drug. Only rare occurrences of isolates displaying MIC values higher than the susceptible breakpoint have been described.^[@DKQ087C20],[@DKQ087C91]^ Moreover, enterococci with daptomycin MICs \> 4 mg/L (CLSI susceptible breakpoint of ≤4 mg/L) are often designated as resistant or as non-susceptible.

Few *in vitro* resistance studies have been performed with daptomycin and enterococci, and the mechanism underpinning this resistance remains to be elucidated. Spontaneous resistance to daptomycin in enterococci occurs rarely *in vitro*, with frequencies \<10^−9^.^[@DKQ087C92]^ In one study, enterococci and staphylococci obtained from agar plates that contained daptomycin (at concentrations above the MIC) failed to grow when subcultured on daptomycin-containing agar plates. After purification on agar plates without daptomycin, these bacteria exhibited MICs identical to those for the parent strains. This suggested that susceptibility to daptomycin is heterogeneous.^[@DKQ087C92]^

Daptomycin-non-susceptible *E. faecium* (with an MIC of 6 mg/L) was recovered from a patient with bacteraemia who had no previous exposure to daptomycin.^[@DKQ087C93]^ However, the study did not investigate the potential mechanisms underlying the reduced susceptibility of daptomycin. Treatment failures of enterococcal infections associated with reduced daptomycin susceptibility have been reported (Table [4](#DKQ087TB4){ref-type="table"}),^[@DKQ087C94]--[@DKQ087C100]^ including five cases of bacteraemia^[@DKQ087C94],[@DKQ087C95],[@DKQ087C98]--[@DKQ087C100]^ and two cases of endocarditis.^[@DKQ087C96],[@DKQ087C97]^ The majority of these infections were due to VRE.^[@DKQ087C94]--[@DKQ087C96],[@DKQ087C98]--[@DKQ087C100]^ In six out of these seven treatment failure cases, patients had received daptomycin treatment prior to the detection of a resistant strain, suggesting that the resistance developed during treatment;^[@DKQ087C95]--[@DKQ087C100]^ however, it is difficult to draw firm conclusions regarding this because baseline MICs for daptomycin were not available in most cases.^[@DKQ087C94]--[@DKQ087C97],[@DKQ087C99],[@DKQ087C100]^ The daptomycin MICs for these *E. faecium* and *E. faecalis* isolates ranged from \>8 to \>32 mg/L^[@DKQ087C94],[@DKQ087C98],[@DKQ087C99]^ and from \>8 to 32 mg/L,^[@DKQ087C96],[@DKQ087C97],[@DKQ087C100]^ respectively. The conditions of these patients were complicated by other underlying diseases. Five of these cases involved foreign bodies,^[@DKQ087C95]--[@DKQ087C98],[@DKQ087C100]^ and the removal of prosthetic devices was delayed in four cases.^[@DKQ087C95]--[@DKQ087C98]^ Furthermore, the daptomycin doses used in three of six cases with a known dosing regimen were \<6 mg/kg every 24 h, which may be suboptimal for the treatment of enterococcal endocarditis or bacteraemia (the CLSI susceptibility breakpoint and the EUCAST epidemiology cut-off value for enterococci are greater than that for *S. aureus*).^[@DKQ087C12],[@DKQ087C19],[@DKQ087C20],[@DKQ087C87],[@DKQ087C101],[@DKQ087C102]^

###### 

Case reports of infections with daptomycin-non-susceptible enterococci isolates

  Patient                                                                    Indication for DAP use                                                                                                                                                                                                                                                                                                                                                         
  --------------------------------------- ---------------------------------- ------------------------------------------------ --------------------------------------- ----------------------------- ----------------------------------------------------------------------- ---------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------- ---------------
  53                                      M                                  NR                                               VAN-resistant *E. faecalis*             endocarditis (mitral valve)   6 mg/kg every 24 h for 8 weeks (followed by mitral valve replacement)   \>8 (Etest)            prior: NAF, VAN                                                                           bacteraemia 10 days after discharge and died soon afterwards   [@DKQ087C96]
  follow-on: LZD                                                                                                                                                                                                                                                                                                                                                                                                                                            
  55                                      F                                  diabetes mellitus, haemodialysis, AICD           *E. faecalis*                           endocarditis (aortic valve)   6 mg/kg every 48 h                                                      32 (microdilution)     follow-on: AMP, GEN, aortic valve replacement, tricuspid valvuloplasty, removal of AICD   cured                                                          [@DKQ087C97]
  22                                      M                                  Hodgkin\'s lymphoma, AML, testicular carcinoma   VAN-resistant *E. faecium*, *E. coli*   bacteraemia                   6 mg/kg every 24 h for 17 days                                          \>32 (microdilution)   prior: DOX, FEP, VAN, metronidazole                                                       cured                                                          [@DKQ087C98]
  concomitant: MEM                                                                                                                                                                                                                                                                                                                                                                                                                                          
  follow-on: LZD, DOX, catheter removal                                                                                                                                                                                                                                                                                                                                                                                                                     
  37                                      F                                  AML                                              VAN-resistant *E. faecium*              bacteraemia                   6 mg/kg for 17 days                                                     \>32 (microdilution)   prior: TZP, GEN, VAN, AMB, VRC                                                            recurrence of VRE bacteraemia                                  [@DKQ087C99]
                                          follow-on: LZD, catheter removal                                                                                                                                                                                                                                                                                                                                                                                  
  62                                      F                                  myelofibrosis, GVHD                              VAN-resistant *E. durans*               bacteraemia                   6 mg/kg every 48 h for 20 days                                          32 (Etest)             prior: FEP, LVX                                                                           cured                                                          [@DKQ087C95]
  follow-on: LZD, catheter removal                                                                                                                                                                                                                                                                                                                                                                                                                          
  NR                                      M                                  Crohn\'s disease                                 VAN-resistant *E. faecium*              bacteraemia                   NR                                                                      16 (Etest)             prior: Q/D                                                                                NR                                                             [@DKQ087C94]
  64                                      F                                  cryptogenic cirrhosis, haemodialysis             VAN-resistant *E. faecalis*             bacteraemia                   400 mg every 48 h for ∼14 days                                          16 (microdilution)     prior: LZD                                                                                died                                                           [@DKQ087C100]
  concomitant: AMK                                                                                                                                                                                                                                                                                                                                                                                                                                          
  follow-on: LZD, AMP                                                                                                                                                                                                                                                                                                                                                                                                                                       

AICD, automated implantable cardioverter-defibrillator; AMB, amphotericin B; AMK, amikacin; AML, acute myeloid leukaemia; AMP, ampicillin; DAP, daptomycin; DOX, doxycycline; F, female; FEP, cefepime; GEN, gentamicin; GVHD, graft-versus-host disease; LVX, levofloxacin; LZD, linezolid; M, male; MEM, meropenem; NAF, nafcillin; NR, not reported; Q/D, quinupristin/dalfopristin; TZP, piperacillin/tazobactam; VAN, vancomycin; VRC, voriconazole; VRE, vancomycin-resistant enterococci.

Conclusions {#s6}
===========

Treatment for enterococcal infections is becoming increasingly challenging, because enterococci may develop resistance to existing therapies and there is a paucity of therapeutic options against multidrug-resistant enterococci. Using the CLSI breakpoint of ≤4 mg/L and the EUCAST epidemiological cut-off value of 4 mg/L, microbiological data show that the large majority of clinical enterococcal isolates are susceptible to daptomycin. Furthermore, daptomycin is not associated with cross-resistance to other antimicrobials and is active against most isolates of antibiotic-resistant enterococci, including VRE. Current clinical practice suggests that daptomycin alone or combined with other agents can achieve favourable outcomes in patients with enterococcal infections, including those with multiple co-morbidities. Further clinical experience, including additional safety and efficacy studies with higher doses of daptomycin (8--12 mg/kg), will be useful in better characterizing the role of daptomycin in enterococcal infections.
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